Personalized Medicine in Psychiatry Personalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report  Erin Green, Andrea N. Goldstein-Piekarski, Alan F. Schatzberg, A. John Rush, Jun Ma, Leanne Williams  Personalized Medicine in Psychiatry   Volume 1, Pages 65-73 (March 2017) DOI: 10.1016/j.pmip.2016.12.001 Copyright © 2016 Terms and Conditions

Fig. 1 Predicted probabilities of remission for each treatment at different levels of Body Mass Index (BMI). Probabilities were calculated at the midpoint of the normal range (21.7kg/m2), overweight (27.5kg/m2), obese class I (32.5kg/m2), obese class II (37.5kg/m2) and at two points within the range of obese class III (42.5kg/m2 and 50kg/m2). Of note, the relationship between BMI and prediction of remission was only significant for venlafaxine-XR. However, predicted probabilities are shown for each treatment arm here. Personalized Medicine in Psychiatry  2017 1, 65-73DOI: (10.1016/j.pmip.2016.12.001) Copyright © 2016 Terms and Conditions

Fig. 2 Predicted probabilities of remission for males and females collapsed across treatment at differing levels of Body Mass Index (BMI). Personalized Medicine in Psychiatry  2017 1, 65-73DOI: (10.1016/j.pmip.2016.12.001) Copyright © 2016 Terms and Conditions

Fig. 3 Flow chart demonstrating the predicted probability for every combination of sex, obesity classification calculated at the midpoint of the normal range (21.7kg/m2), overweight (27.5kg/m2), obese class I (32.5kg/m2), obese class II (37.5kg/m2) and obese class III (42.5kg/m2). Predicted probabilities lower than 40% are highlighted in red and probabilities greater than 70% are highlighted in green. Abbreviations: NM=normal; OW=overweight; OB=obese; ESC=escitalopram; SER=sertraline; VEN=venlafaxine-XR. Personalized Medicine in Psychiatry  2017 1, 65-73DOI: (10.1016/j.pmip.2016.12.001) Copyright © 2016 Terms and Conditions